RATIONALE: Several new therapeutic strategies have been described for the treatment of sepsis, but to date none are related to alterations in the bombesin/gastrin-releasing peptide (GRP) receptor pathways. OBJECTIVES: To determine the effects of a selective GRP receptor antagonist, RC-3095, on cytokine release from macrophages and its in vivo effects in the cecal ligation and puncture (CLP) model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. METHODS: We determined the effects of RC-3095 in the CLP model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. In addition, we determined the effects of RC-3095 on tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-10, and nitric oxide release from activated macrophages. MEASUREMENTS AND MAIN RESULTS: The GRP antagonist attenuated LPS- or CLP-induced TNF-alpha, IL-1beta, and nitric oxide release in cultured macrophages and decreased the mRNA levels of inducible nitric oxide synthase. The administration of RC-3095 (0.3 mg/kg) 6 h after sepsis induction improved survival in the CLP model, and diminished lung damage after intratracheal instillation of LPS. These effects were associated with attenuation on the circulating TNF-alpha and IL-1beta levels and decreased myeloperoxidase activity in several organs. CONCLUSIONS: We report that a selective GRP receptor antagonist attenuates the release of proinflammatory cytokines in vitro and in vivo and improves survival in "established" sepsis. These are consistent with the involvement of a new inflammatory pathway relevant to the development of sepsis.
RATIONALE: Several new therapeutic strategies have been described for the treatment of sepsis, but to date none are related to alterations in the bombesin/gastrin-releasing peptide (GRP) receptor pathways. OBJECTIVES: To determine the effects of a selective GRP receptor antagonist, RC-3095, on cytokine release from macrophages and its in vivo effects in the cecal ligation and puncture (CLP) model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. METHODS: We determined the effects of RC-3095 in the CLP model of sepsis and in acute lung injury induced by intratracheal instillation of LPS. In addition, we determined the effects of RC-3095 on tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-10, and nitric oxide release from activated macrophages. MEASUREMENTS AND MAIN RESULTS: The GRP antagonist attenuated LPS- or CLP-induced TNF-alpha, IL-1beta, and nitric oxide release in cultured macrophages and decreased the mRNA levels of inducible nitric oxide synthase. The administration of RC-3095 (0.3 mg/kg) 6 h after sepsis induction improved survival in the CLP model, and diminished lung damage after intratracheal instillation of LPS. These effects were associated with attenuation on the circulating TNF-alpha and IL-1beta levels and decreased myeloperoxidase activity in several organs. CONCLUSIONS: We report that a selective GRP receptor antagonist attenuates the release of proinflammatory cytokines in vitro and in vivo and improves survival in "established" sepsis. These are consistent with the involvement of a new inflammatory pathway relevant to the development of sepsis.
Authors: Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen Journal: Peptides Date: 2015-05-11 Impact factor: 3.750
Authors: Fabricia Petronilho; Francieli Vuolo; Letícia Selinger Galant; Larissa Constantino; Cristiane Damiani Tomasi; Vinicius Renne Giombelli; Cláudio Teodoro de Souza; Sabrina da Silva; Denise Frediani Barbeiro; Francisco Garcia Soriano; Emílio Luiz Streck; Cristiane Ritter; Alfeu Zanotto-Filho; Matheus Augusto Pasquali; Daniel Pens Gelain; José Luiz Rybarczyk-Filho; José Cláudio Fonseca Moreira; Norman L Block; Rafael Roesler; Gilberto Schwartsmann; Andrew V Schally; Felipe Dal-Pizzol Journal: Mol Med Date: 2012-10-24 Impact factor: 6.354
Authors: Fabricia Petronilho; Bruna de Souza; Francieli Vuolo; César A F Benetton; Emilio L Streck; Rafael Roesler; Gilberto Schwartsmann; Felipe Dal-Pizzol Journal: Inflamm Res Date: 2010-04-03 Impact factor: 4.575
Authors: Juciano Gasparotto; Carolina S Girardi; Nauana Somensi; Camila T Ribeiro; José C F Moreira; Monique Michels; Beatriz Sonai; Mariane Rocha; Amanda V Steckert; Tatiana Barichello; João Quevedo; Felipe Dal-Pizzol; Daniel P Gelain Journal: J Biol Chem Date: 2017-11-10 Impact factor: 5.157
Authors: Rafael Sanguinetti Czepielewski; Bárbara Nery Porto; Lucas Bortolotto Rizzo; Rafael Roesler; Ana Lúcia Abujamra; Larissa Garcia Pinto; Gilberto Schwartsmann; Fernando de Queiroz Cunha; Cristina Bonorino Journal: Proc Natl Acad Sci U S A Date: 2011-12-27 Impact factor: 11.205
Authors: Dennis Rosen; Jong-Hwan Lee; Frank Cuttitta; Fatema Rafiqi; Simone Degan; Mary E Sunday Journal: Am J Respir Crit Care Med Date: 2006-03-30 Impact factor: 21.405
Authors: Omar J Cassol; Gislaine T Rezin; Fabrícia C Petronilho; Giselli Scaini; Cinara L Gonçalves; Gabriela K Ferreira; Rafael Roesler; Gilberto Schwartsmann; Felipe Dal-Pizzol; Emilio L Streck Journal: Neurochem Res Date: 2010-04 Impact factor: 3.996
Authors: Khalid Ashour; Lin Shan; Jong Hwan Lee; William Schlicher; Keiji Wada; Etsuko Wada; Mary E Sunday Journal: Am J Respir Crit Care Med Date: 2006-04-07 Impact factor: 21.405
Authors: Daniel C Damin; Frederico S Santos; Renata Heck; Mário A Rosito; Luise Meurer; Lúcia M Kliemann; Rafael Roesler; Gilberto Schwartsmann Journal: Dig Dis Sci Date: 2009-11-06 Impact factor: 3.199